Item Type | Name |
Academic Article
|
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
|
Concept
|
CDC2-CDC28 Kinases
|
Concept
|
Cyclin-Dependent Kinase 8
|
Concept
|
p38 Mitogen-Activated Protein Kinases
|
Concept
|
Cyclin-Dependent Kinases
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
Concept
|
CDC2 Protein Kinase
|
Concept
|
Cyclic AMP-Dependent Protein Kinases
|
Concept
|
Protein Kinases
|
Concept
|
Cyclin-Dependent Kinase 2
|
Concept
|
MAP Kinase Kinase Kinases
|
Concept
|
Cyclin-Dependent Kinase 4
|
Concept
|
Cyclin-Dependent Kinase 9
|
Concept
|
MAP Kinase Signaling System
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
Concept
|
Mitogen-Activated Protein Kinase 10
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p27
|
Academic Article
|
Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
|
Academic Article
|
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange.
|
Academic Article
|
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
|
Academic Article
|
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
|
Academic Article
|
Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
|
Academic Article
|
Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
|
Academic Article
|
Structural and biochemical studies of human proliferating cell nuclear antigen complexes provide a rationale for cyclin association and inhibitor design.
|
Academic Article
|
Progress in the discovery of polo-like kinase inhibitors.
|
Academic Article
|
Strategies for the design of potent and selective kinase inhibitors.
|
Academic Article
|
Protein structures in virtual screening: a case study with CDK2.
|
Academic Article
|
Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
|
Academic Article
|
Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
|
Academic Article
|
Improved lead-finding for kinase targets using high-throughput docking.
|
Academic Article
|
Catch the kinase conformer.
|
Academic Article
|
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance.
|
Academic Article
|
REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.
|
Academic Article
|
Progress in the evaluation of CDK inhibitors as anti-tumor agents.
|
Academic Article
|
Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics.
|
Academic Article
|
Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
|
Academic Article
|
Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
|
Academic Article
|
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.
|
Academic Article
|
Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.
|
Academic Article
|
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents.
|
Academic Article
|
PLK1 as an oncology target: current status and future potential.
|
Academic Article
|
Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.
|
Academic Article
|
Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.
|
Academic Article
|
Current assessment of polo-like kinases as anti-tumor drug targets.
|
Academic Article
|
Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
|
Academic Article
|
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
|
Academic Article
|
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
|
Academic Article
|
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
|
Academic Article
|
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.
|
Academic Article
|
Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.
|
Academic Article
|
Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop.
|
Academic Article
|
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
|
Concept
|
Aurora Kinase A
|
Concept
|
Aurora Kinases
|
Academic Article
|
PharmaDiscovery 2005. Kinases in drug discovery.
|
Academic Article
|
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
|
Academic Article
|
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
|
Academic Article
|
A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
|
Academic Article
|
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer.
|